key: cord-1047521-9bbs1m3p authors: Seligman, Henry; Sen, Sayan; Nijjer, Sukhjinder; Al-Lamee, Rasha; Clifford, Piers; Sethi, Amarjit; Hadjiloizou, Nearchos; Kaprielian, Raffi; Ramrakha, Punit; Bellamy, Michael; Khan, Masood A; Kooner, Jaspal; Foale, Rodney A; Mikhail, Ghada; Baker, Christopher S; Mayet, Jamil; Malik, Iqbal; Khamis, Ramzi; Francis, Darrel; Petraco, Ricardo title: Management of Acute Coronary Syndromes During the Coronavirus Disease 2019 Pandemic: Deviations from Guidelines and Pragmatic Considerations for Patients and Healthcare Workers date: 2020-11-24 journal: Interv Cardiol DOI: 10.15420/icr.2020.21 sha: 56d27865b471f591307cce3f3007a48d792fc8d9 doc_id: 1047521 cord_uid: 9bbs1m3p Coronavirus disease 2019 (COVID-19) is forcing cardiology departments to rapidly adapt existing clinical guidelines to a new reality and this is especially the case for acute coronary syndrome pathways. In this focused review, the authors discuss how COVID-19 is affecting acute cardiology care and propose pragmatic guideline modifications for the diagnosis and management of acute coronary syndrome patients, particularly around the appropriateness of invasive strategies as well as length of hospital stay. The authors also discuss the use of personal protective equipment for healthcare workers in cardiology. Based on shared global experiences and growing peer-reviewed literature, it is possible to put in place modified acute coronary syndrome treatment pathways to offer safe pragmatic decisions to patients and staff. patients, even in the absence of chest pain, with fulminant myocarditis being reported as directly responsible for up to 7% of COVID-19-related deaths. [14] [15] [16] As per data available on 9 April 2020, close to 20,000 COVID-19 patients were hospitalised in the UK, which would create approximately 4,000 new 'false diagnoses' of ACS. 17 Thus, while the incidence of true ACS cases has fallen since the beginning of the pandemic -possibly due to patients' reluctance to attend hospitalcases of late-presenting MI and its complications have been described. [18] [19] [20] Finally, healthcare workers working in cardiology face a higher than average risk of contamination, particularly those involved in potential aerosol-generating procedures (AGPs). 21 This risk is especially high during ambulance transportation and echocardiography (because of close patient interaction) and urgent percutaneous interventions. 7, 22, 23, 24 For ease of display we present the ACS pathways being used at our centre (Imperial College NHS Healthcare Trust, London, UK) as schematic flowcharts. Figure 1 displays the adapted pathway for the treatment of patients presenting with ST-elevation MI (STEMI) and high-risk ACS and Figure 2 shows the modified pathway for non-STEMI (NSTEMI) and ACS. We briefly discuss the reasoning behind the most important deviations from guidelines, providing peer-reviewed evidence whenever possible. Our ACS pathways have been subjected to regional debates at the pan-London Heart Attack Centre Group and open public discussions at the Imperial College COVID-19 webinar, as well as on social media platforms and societal web content. [25] [26] [27] Our modified pathway to treat patients presenting with a STEMI or high-risk ACS is presented in Figure 1 . The most relevant points for discussion are described in the following sections. Due to their high mortality and risk of transportation (for patients and staff), severely ill COVID-19 patients in ICU (patients requiring invasive organ support) who develop a STEMI or high-risk ACS should not be considered immediate candidates for emergency percutaneous revascularisation. Fibrinolysis could be considered on an individual basis following discussion with a senior colleague. If feasible, a rapid electronic multidisciplinary team meeting should occur between the clinicians involved, including intensivist, interventional cardiologist and general cardiologist, so that therapy can be administered in a timely fashion. Up to the point of this paper being drafted, there is no approved pointof-care test for COVID-19 infection. Therefore, we suggest that patients presenting via ambulance with suspected STEMI should be assessed outside the arriving centre. In the UK, Heart Attack Centres such as our own are often based in separate units without general emergency care and so triage accordingly. If the case is clearly not cardiac based upon clinical grounds and ECG, patients should be diverted to the appropriate emergency department. This will avoid unnecessary viral exposure of hospital staff and ambulance crew caused by taking patients out of the ambulance. In centres with both emergency medicine and STEMI care, the decision is made between departments rather than between centres. COVID-19 can present as a STEMI-mimic myocarditis picture. 13 Although this will result in emergency angiograms showing nonoccluded coronaries, we judge that the only way of accurately reaching this diagnosis is via exclusion of STEMI. Therefore, the consideration of myocarditis as a differential diagnosis should not delay efforts to offer percutaneous reperfusion in possible COVID-19 patients presenting with chest pain and regional ST elevation on ECG. Radial angiography is recommended to reduce the risk of femoral bleeding complications. Primary percutaneous coronary intervention (PPCI) should remain the preferred choice of revascularisation for STEMI during the COVID-19 pandemic. However, confirmed or highly suspicious COVID-19 patients (red box category on Figure 1 ) should be considered for fibrinolysis with staged PCI, particularly if the following clinical and/or logistical circumstances are present: the patient is not in a cardiac centre and transportation is likely to increase door-to-balloon time by more than 60-90 minutes; STEMI is not anterior and not involving a large myocardial territory on ECG; bleeding risk is low; patient is hypoxic and a potential high risk for generating aerosols during high-flow oxygen therapies, intubation or cardiopulmonary resuscitation; and there are no contraindications for thrombolysis. The rationale for considering lysis therapy in such circumstances is the following: the survival benefit of PPCI over lysis is important but small -in the region of 2% absolute risk reduction in non-COVID-19 patients. 28, 29 Therefore it is likely that such benefit may be smaller or even abolished when an underlying pathology of high mortality, such as COVID-19 is present leading to inevitable delays in PCI reperfusion, caused by the inevitable delays in patient transportation and the extra time needed for protecting catheter laboratory staff members. 30 In addition, transportation (from a general hospital to a cardiac centre) of highly infective COVID-19 patients, particularly those requiring high flow oxygen therapy, imposes a very high risk of contamination to healthcare workers, including ambulance crew and catheter laboratory staff. [31] [32] [33] Finally, it is possible that offering PCI after COVID-19 infection has settled (fever, hypoxia, inflammation, etc) would reduce the risk of stent thrombosis. However, we believe it is important that pathways that include fibrinolysis are put in place in advance. Firstly, decisions must be individualised and made by more than one senior physician, with the reasoning for offering lysis over PPCI being Figure 3 and PPE section below). Protection with full PPE should also apply to any close clinical and echocardiographic assessment prior to transfer to the catheter laboratory. Subsequent inpatient management and ward allocation will still be determined by their COVID-19 status or probability of disease; those patients with confirmed or highly suspected COVID-19 should be transferred to appropriate COVID-19 wards. During the pandemic, it is reasonable to adopt a buddy system for rotas, with one consultant on-call and a second on stand-by in case the first one falls ill. In addition, social distancing measures have affected routine implementation of face-to-face discussions among physicians. Therefore, adoption of virtual multidisciplinary teams and data compliant group messaging allows for rapid decision-making deliberations during the pandemic. All discussions should be clearly documented in patients' medical records. The NSTEMI-ACS pathway is presented in Figure 2 . The points in the following sections should be highlighted. in cardiac troponin in a significant proportion of cases -up to 23% of cases in a Chinese cohort. 15 The precise pathophysiological mechanisms behind this myocardial injury has not yet been established, hence optimal management remains unknown. Therefore, the management of If the clinical picture is typical of ACS, management should remain as standard as possible for stable patients, regardless of COVID-19 status. [1] [2] [3] [4] [5] This includes prompt initiation of pharmacological therapy and transfer to a cardiac unit with catheter laboratory facilities. We propose that patients should be offered invasive angiography before discharge, particularly those with raised cardiac biomarkers, high-risk ECG features or regional ventricular abnormalities on echocardiography. While an early conservative discharge on medical therapy alone would reduce hospital stay, the risk of reinfarction is considerable. 43 Furthermore, because a significant proportion of patients will be unwilling to seek hospital attention again because of fears of acquiring COVID-19, we judge that early medical discharge would pose an unacceptably high mortality risk during the pandemic. 44 Therefore, we judge that during the peak of the pandemic, and if financially and logistically viable, the following PPE strategies should be adopted for ACS cases regardless of the patient's COVID-19 status ( Figure 3 ): • Patients should wear a surgical mask during the entire hospital stay, providing it will not affect clinical care. 55 Patients who require oxygen should have controlled doses administered via nasal cannula under the mask. Those requiring higher flows should be considered as an AGP. • Close (<2 m) contact with patients should be restricted to the minimum necessary during ward rounds. • It is reasonable to offer full PPE to all ambulance crew, catheter laboratory staff and echocardiography operators, as well as to acute workers with close clinical contact with the patient (Figure 3 , left panel). • For all other healthcare workers involved with direct patient care, a minimum of basic PPE should be provided (Figure 3, right panel) . • Thought should be given to the ventilation of catheter laboratory and ward areas as a way of promoting aerosol elimination. 21, 31, 49 If departments face an issue of availability of PPE, it would be reasonable to offer basic PPE ( Figure 3 ) to all staff when treating patients with very low probability of COVID-19 infection (green box on Figures 1 and 2) . Importantly, this should be switched to full PPE in the event of AGP during PCI or hospital stay. For instance, patients suffering cardiac arrest would require staff in basic PPE to don full PPE before coming to provide support. Where possible, we have used high quality peer-reviewed data to guide these recommendations. However, at the time of writing, there was an urgent need to respond to an unprecedented medical emergency, which did not allow time for much data of this kind to emerge. Accordingly, we were required to make use of the pool of data available through direct communication, social media and preprints. We have maintained these in our references to remain true to the challenges of that period. The COVID-19 pandemic has forced cardiology departments to review previously established guidelines, particularly those affecting the care of ACS patients. However, based on shared global experiences and growing peer-reviewed literature, it is possible to put in place ACS treatment pathways that offer evidence-based decisions to patients and staff. While pathway modifications could be implemented more rapidly in the future, only further COVID-19 studies will guide us as to whether further modifications are needed. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) AHA/ACC guideline for the management of patients with non-STelevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic An in-hospital pathway for acute coronary syndrome patients during the covid-19 outbreak: Initial experience under real-world suboptimal conditions Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak Critical organizational issues for cardiologists in the Covid-19 outbreak Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis ST-segment elevation in patients with covid-19 -a case series Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic UK government press conference accompanying data Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage Reduced rate of hospital admissions for ACS during Covid-19 outbreak in northern Italy Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review Precautions and procedures for coronary and structural cardiac interventions during the COVID-19 pandemic: guidance from Canadian Association of Interventional Cardiology Management of acute myocardial infarction during the COVID-19 pandemic Imperial College COVID-19 Cardiovascular Conference Huge effort from the int cardio team at @ImperialNHS. ACS #COVID-19 COVID SOP. Under discussion. Previous Twitter peer review made us change 1st lysis agent to tenecteplase. Comments welcome Protect the team: Modify ACS treatment with use of thrombolysis if needed Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction Protecting healthcare workers during the coronavirus disease 2019 (COVID-19) coronavirus outbreak: lessons from Taiwan's severe acute respiratory syndrome response An emergency amendment to the national scope of practice for paramedics in the setting of a global pandemic COVID-19: what paramedics need to know! Improving emergency department flow: reducing turnaround time for emergent CT scans How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital Initiation of a new infection control system for the COVID-19 outbreak Comparison short time discharge with long time discharge following uncomplicated percutaneous coronary intervention for non-ST elevation myocardial infarction patients Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomised controlled trial A randomized trial of anticoagulation strategies in COVID-19 Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a metaanalysis of individual patient data Covid-19: A&E visits in England fall by 25% in week after lockdown NHS urges public to get care when they need it Impact of coronavirus disease 2019 (COVID-19) outbreak on outcome of myocardial infarction in Hong Kong, China Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction Acute coronary thrombosis in a patient with septic shock without any evidence of disseminated intravascular coagulation Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19) New personal protective equipment (PPE) guidance for NHS teams Interpretation of Public Health England (PHE) PPE guidelines in cardiology-specific scenarios This Japanese experiment shows how easily coronavirus can spread -and what you can do about it Universal screening for SARS-CoV-2 in women admitted for delivery Face masks for the public during the covid-19 crisis